Protocol summary

Study aim
Evaluating the effect of Risperidone on the treatment of fecal incontinence in functional constipation in children 4 to 18 years old with neurodevelopmental disorders and children without neuropsychiatric disorders
Design
Random allocation by stratified randomization and using the permuted block randomization method with quadruple and binary blocks was performed. Based on the sample size of 136 subjects, the blocks of size 2 and 4 were produced using the online site (www.sealedenvelope.com). The clinical trial has a control group, with parallel group design and it was double-blind, randomized, phase 3.
Settings and conduct
The study site of pediatric gastrointestinal and psychiatric clinics of Mofid and Loghman hospitals in Tehran, Iran. Blinding: double-blind. In the evaluation phase, researchers could not differentiate intervention from the control group until the end of the study.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Functional constipation; Fecal incontinence; Age between 4 to 18 years old Exclusion criteria: Anatomical or hormonal causes for constipation; Presence of other GI disorders
Intervention groups
Intervention group: receiving Risperidone. The participants received a dose of 0.25-0.5 mg every 12 hours of Risperidone syrup daily for 12 weeks. Control group: receiving placebo. The participants received a dose of 0.25-0.5 mg every 12 hours of placebo syrup daily for 12 weeks.
Main outcome variables
Fecal incontinence

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200203046352N1
Registration date: 2022-06-19, 1401/03/29
Registration timing: retrospective

Last update: 2022-06-19, 1401/03/29
Update count: 0
Registration date
2022-06-19, 1401/03/29
Registrant information
Name
Seyedehleila Tabatabaeifar
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 2222 7021
Email address
leilatabatabaee@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-01-01, 1398/10/11
Expected recruitment end date
2021-01-19, 1399/10/30
Actual recruitment start date
2019-12-22, 1398/10/01
Actual recruitment end date
2021-02-19, 1399/12/01
Trial completion date
2021-06-20, 1400/03/30
Scientific title
Comparison of the effect of Risperidone and placebo in the treatment of fecal incontinence in children 4 -18 years of age suffering from functional constipation and fecal incontinence, with and without neuropsychiatric disorders
Public title
Impact of Risperidone in the treatment of fecal incontinence among children
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Functional constipation Fecal incontinence Age between 4 and 18 neuropsychiatric disorders in half of participants Absence of neuropsychiatric disorders in half of participants
Exclusion criteria:
Anatomical and hormonal causes of constipation Presence of other GI disorders
Age
From 4 years old to 18 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 140
Actual sample size reached: 136
Randomization (investigator's opinion)
Randomized
Randomization description
Considering that BMI Z-score and psychological disorder can have a great impact on the results of the study, to ensure the uniform distribution of these variables in the groups, random allocation by Stratified Randomization and using the Permuted block randomization method with quadruple and binary blocks were used. Based on the sample size of 136 subjects, the quadruple block or double block were produced using the online site (www.sealedenvelope.com). Due to the double-blindness of the study, before starting the study, sets of packages containing Risperidone were prepared by someone other than the researcher, and the placebo was similar in appearance to Risperidone syrup. Indeed, researchers in the evaluation phase, from the allocation of participants in each of the groups (intervention and control group) until the end of the intervention, were not know the groups whereby the patients were randomized. In order to apply concealment in the randomization process, unique codes were used on the medicine boxes, and the desired code is also generated by the software. With this method of concealment, none of the participants and researchers know which of the two groups received the Risperidone or placebo. These codes were inserted on the packages by the company receiving the supplements and placebos. Upon each person entering the study, based on the sequence generated, the drug package in which the code is recorded was assigned to the parents. Also, the random sequence generated during the study was unpredictable.
Blinding (investigator's opinion)
Double blinded
Blinding description
Medicine and placebo look exactly the same(shape, size, colour, smell). None of the participants are informed of receiving a placebo. Other than the manufacturer, nobody can differentiate medicine from a placebo.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Pajoohan Ethics committee of Shahid Beheshti University of Medical Sciences
Street address
Shahid Beheshti University of Medical Sciences, Koodakyaar dead end alley, Daaneshjoo Blvd, Chamraan highway
City
Tehran
Province
Tehran
Postal code
1985717443
Approval date
2020-01-04, 1398/10/14
Ethics committee reference number
IR.SBMU.MSP.REC.1398.833

Health conditions studied

1

Description of health condition studied
Functional constipation, Fecal incontinence, NDD
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
fecal incontinence
Timepoint
every month for 6 months
Method of measurement
interview with parents

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: 34 patients with functional constipation and fecal incontinence who receive a daily dose of 0.25-0.5 mg (every 12 hours) of risperidone syrup for 12 weeks.
Category
Treatment - Drugs

2

Description
Control group: 34 patients with functional constipation and fecal incontinence who receive a daily dose of 0.25-0.5 mg (every 12 hours) of placebo
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Pediatrics GI and psychiatry clinic,Mofid Children Hospital, Pediatrics GI clinic; Loghman Hospital
Full name of responsible person
Dr. Ghazaal Zahed
Street address
Mofid Chidren's Hospital, Shariati St., Tehran
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
+98 21 2222 7021
Fax
+98 21 2222 0254
Email
ghazal.zahed@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Ghazaal Zaahed
Street address
Shahid Arabi ave., Daneshjoo Blvd.,Velenjak, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Fax
Email
info@sbmu.ac.ir
Web page address
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Ghazaal Zaahed
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Psychiatrics
Street address
Mofid Chidren's Hospital, Shariati street, Tehran
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
+98 21 2222 7021
Email
ghazal.zahed@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Ghazaal Zaahed
Position
assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Psychiatrics
Street address
Mofid Chidren's Hospital, Shariati street, Tehran
City
Tehran
Province
Tehran
Postal code
1546815524
Phone
+98 21 2222 7021
Email
ghazal.zahed@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Ghazaal Zaahed
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Psychiatrics
Street address
Mofid Chidren's Hospital, Shariati street, Tehran
City
Tehran
Province
Tehran
Postal code
1546815524
Phone
+98 21 2222 7021
Email
ghazal.zahed@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
We would like to share every document that will be resulted in this research by considering our patients personal information that are secret. Demographic data,signs and symptoms anf effect of our treatment
When the data will become available and for how long
After finalizing the research and evaluation the results and for unlimited time
To whom data/document is available
Gastroenterologist (adults and pediatrics) pediatricians, pediatric and general surgeons
Under which criteria data/document could be used
By considering patients information as secret file
From where data/document is obtainable
Pediatric gastroenterology,hepatology and nutrition research center ,Shahid Beheshti University of Medical Sciences,Tehran,Iran
What processes are involved for a request to access data/document
By formal e-mail
Comments
none
Loading...